Hyperphosphatemia in Chronic Kidney Disease: Patient Characteristics and Dialysis Mortality during the First Year of Dialysis
Emmanuelle Laurain*, Nathalie Thilly, Stephanie Boini, Michele Kessler, Serge Briançon and Luc Frimat
Clinical Epidemiology and Evaluation, CIC-EC CIE6 Inserm, University Hospital of Nancy, Nancy University, P. Verlaine–Metz University, Paris-Descartes University, EA 4360 Apemac, Nancy, and Nephrology Unit, University Hospital of Nancy, France
- *Corresponding Author:
- Emmanuelle Laurain
Service d’Epidémiologie et Evaluation cliniques–CHU de Nancy,
Hôpitaux de Brabois
Allée du Morvan-54500 Vandoeuvre-lès-Nancy, France
Tel: +33 3-83-85-21-63
Fax: +33 3-83-85-12-05
E-mail: [email protected]
Received Date: February 23, 2012; Accepted Date: July 23, 2012; Published Date: July 26, 2012
Citation: Laurain E, Thilly N, Boini S, Kessler M, Briançon S, et al. (2012) Hyperphosphatemia in Chronic Kidney Disease: Patient Characteristics and Dialysis Mortality during the First Year of Dialysis. J Nephrol Therapeutic S3:009. doi:10.4172/2161-0959.S3-009
Copyright: © 2012 Laurain E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aims: To describe the characteristics of chronic kidney disease patients with hyperphosphatemia before dialysis. To assess the impact of pre-dialysis hyperphosphatemia on dialysis mortality.
Methods: All patients beginning a dialysis treatment in 2005-2006 in all the nephrology units operating in the Lorraine region of northeastern France were considered. Among them, those who were referred to a nephrologist more than 1 month before dialysis and had atleast one pre-dialysis phosphatemia measurement were included. All-cause mortality during the first year of dialysis was the outcome of interest and phosphatemia level the parameter of interest.
Results: Of 406 patients included (mean age, 68.2 ± 14.8 years), 53% had pre-dialysis hyperphosphatemia, defined by a mean serum phosphate > 1.45 mmol/L during an average pre-dialysis nephrology follow-up period of 10 months. Patients with hyperphosphatemia were younger than those with normophosphatemia, and more often women. They were more likely to have diabetic nephropathy, less likely to have hypertensive nephropathy and cardiovascular comorbidity, and had fewer comorbidities. We found no association between hyperphosphatemia and mortality.
Conclusions: This study shows that patients with pre-dialysis hyperphosphatemia differ from those with normophosphatemia. Larger studies are warranted to confirm or refute the absence of a relationship between predialysis hyperphosphatemia and dialysis mortality.